ARC1779, a novel aptamer therapeutic agent, is indicated for the treatment of a rare, life-threatening blood disorder known as thrombotic thrombocytopenic purpura, or TTP.
ARC1779 is currently in Phase II clinical development with a clinical trial designed to assess the safety, pharmacokinetics and pharmacodynamic effects of ARC1779 in approximately 28 patients with vWF-mediated platelet function disorders, including acute TTP.
Errol DeSouza, president and CEO of Archemix, said: “To date we have been encouraged by ARC1779’s early-stage clinical results, and we continue to believe it has the potential to offer a new and effective treatment in a disease for which there is currently no drug therapy available.”